Resilience, the French Startup, announced that it has raised 45 million dollars in a Series A round led by Cathay Innovation. The Startup wants to improve the treatment journey of patients who have been diagnosed with cancer so that they live a healthier and longer life.
In addition to Cathay Innovation, Singular, which has invested in the Resilience project in the past, also participated in the recent funding round. At the same time, other funds, such as Exor Seeds, Picus Capital and Seaya Ventures, as well as some investors specializing in the healthcare sector such as Fondation Santé Service, MACSF, Ramsay Santé and Vivalto Ventures, gave a “vote of confidence” to healthtech Startup.
The company, behind which are the well-known French entrepreneurs Céline Lazorthes and Jonathan Benhamou, wants to help both patients and healthcare professionals in the treatment of cancer.
As far as the patient is concerned, the app of the French Startup helps users to understand and cope with the effects of the disease and the side effects of the treatments. Users can track various data in the app and find content and information about their illness.
Resilience isn’t just an app that you use at home. It is also a SaaS solution for hospitals so that they can better personalize their treatments. Resilience has been founded in partnership with Gustave Roussy, one of the leading cancer research institutes in the world.
Practitioners will be able to take advantage of all the data that patients have gathered from the app. This way, the specialized doctors that deal with cancer treatment understand the patient better and can adapt their care more quickly and effectively. Resilience has acquired Betterise to gain a head start when it comes to data-driven cancer care.
Resilience’s long-term vision is even more ambitious. A permanent problem for caregivers in cancer treatment units is the lack of time to inform.
Given the needs of patients and the huge workload it is becoming increasingly difficult for doctors to keep track of developments in new treatments that are becoming more and more specialized. Resilience has set itself the goal of addressing this problem by exploiting the potential of data.